targeted alpha therapy tat offers potential inhibit growth micrometastases selectively killing isolated preangiogenic clusters cancer cells practicality efficacy tat tested vitro vivo studies melanoma leukaemia colorectal breast prostate cancers phase NUMBER trial intralesional tat melanoma radioisotope used eluted generator chelated cancer specific monoclonal antibody mab protein plasminogen activator pai2 form ac stable produced tested specificity cytotoxicity vitro melanoma NUMBER mab leukaemia wm60 colorectal c306 breast pai2 herceptin ovarian pai2 herceptin c595 prostate pai2 j591 pancreatic pai2 c595 cancers subcutaneous inoculation million human cancer cells flanks nude mice causes tumours grow mice tumour growth compared untreated controls nonspecific ac specific ac local subcutaneous systemic tail vein intraperitoneal injection models ac injected secondary skin melanomas stage NUMBER patients dose escalation study determine effective tolerance dose measure kinematics obtain equivalent dose organs vitro studies tat orders magnitude cytotoxic targeted cells acs specific beta emitting conjugates free isotopes vivo local tat NUMBER days completely prevents tumour formation cancers tested far tat completely regress advanced sc melanoma successful breast prostate cancers systemic tat inhibits growth sc melanoma xenografts gives complete control breast prostate cancer tumour growth intralesional doses NUMBER microci human patients effective regressing melanomas concomitant complications results point application local systemic tat management secondary cancer results phase NUMBER clinical trial tat subcutaneous secondary melanoma indicate proof principle tat make tumours patients regress alpha emitting bi NUMBER ac NUMBER inhibitor NUMBER alpha conjugate alpha acs NUMBER NUMBER 213bi NUMBER non specific post inoculation intra lesional